FULVICIN P/G 165 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fulvicin P/g 165, and when can generic versions of Fulvicin P/g 165 launch?
Fulvicin P/g 165 is a drug marketed by Chartwell Rx and is included in one NDA.
The generic ingredient in FULVICIN P/G 165 is griseofulvin, ultramicrosize. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the griseofulvin, ultramicrosize profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fulvicin P/g 165
A generic version of FULVICIN P/G 165 was approved as griseofulvin, ultramicrosize by MOUNTAIN on January 9th, 2014.
US Patents and Regulatory Information for FULVICIN P/G 165
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Rx | FULVICIN P/G 165 | griseofulvin, ultramicrosize | TABLET;ORAL | 061996-003 | Apr 6, 1982 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
